Related Experiment Video

Updated: Aug 10, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Antisense therapy in malignant diseases: status quo and quo vadis?

Ingo Tamm1

  • 1Department for Haematology and Oncology, Charité, Campus Virchow, Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. ingo.tamm@charite.de

Clinical Science (London, England : 1979)
|March 11, 2006
PubMed

Insights

Antisense oligonucleotides (AS ODNs) show therapeutic potential for cancers by selectively blocking target mRNA. Clinical trials are evaluating AS ODNs for various malignancies, demonstrating good tolerability and promising activity.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Antisense oligonucleotides (AS ODNs) leverage sequence-specific mRNA binding to inhibit gene expression.
  • This technology offers a targeted approach to modulate genes implicated in cancer development.
  • Approved AS ODN therapies exist, with others in clinical development for various cancers.

Purpose of the Study:

  • To review therapeutic strategies utilizing AS ODNs for malignant diseases.
  • To summarize current clinical studies involving AS ODNs in oncology.
  • To identify novel molecular targets for AS ODN-based cancer therapies.

Main Methods:

  • Review of preclinical and clinical studies on AS ODNs in cancer.
  • Analysis of AS ODN mechanisms, including translational arrest.
  • Examination of clinical trial data for AS ODNs targeting specific genes (e.g., Bcl-2, XIAP, TGF-beta-2).

Main Results:

  • AS ODNs are well-tolerated and demonstrate therapeutic activity in preclinical and clinical settings.
  • Several AS ODNs targeting key cancer-related genes are in clinical trials.
  • An AS ODN targeting Bcl-2 has advanced to Phase III trials for hematologic and solid tumors.

Conclusions:

  • AS ODNs represent a promising therapeutic modality for treating malignancies.
  • Targeted modulation of gene expression via AS ODNs is effective in cancer therapy.
  • Ongoing research continues to explore new targets and refine AS ODN applications in oncology.

More Related Videos

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...